Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Revenue (2016 - 2025)

Ironwood Pharmaceuticals' Revenue history spans 16 years, with the latest figure at $47.7 million for Q4 2025.

  • For Q4 2025, Revenue fell 47.31% year-over-year to $47.7 million; the TTM value through Dec 2025 reached $296.2 million, down 15.72%, while the annual FY2025 figure was $296.2 million, 15.72% down from the prior year.
  • Revenue for Q4 2025 was $47.7 million at Ironwood Pharmaceuticals, down from $122.1 million in the prior quarter.
  • Across five years, Revenue topped out at $122.1 million in Q3 2025 and bottomed at $41.1 million in Q1 2025.
  • The 5-year median for Revenue is $100.6 million (2021), against an average of $95.7 million.
  • The largest YoY upside for Revenue was 33.26% in 2025 against a maximum downside of 47.31% in 2025.
  • A 5-year view of Revenue shows it stood at $117.1 million in 2021, then decreased by 8.48% to $107.2 million in 2022, then rose by 9.66% to $117.6 million in 2023, then fell by 22.98% to $90.5 million in 2024, then tumbled by 47.31% to $47.7 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Revenue are $47.7 million (Q4 2025), $122.1 million (Q3 2025), and $85.2 million (Q2 2025).